EE03017B1 - Kõrge eriaktiivsusega ja teraapiliseks kasutamiseks sobiv vere XI hüübimisteguri kontsentraat ning meetod selle saamiseks - Google Patents

Kõrge eriaktiivsusega ja teraapiliseks kasutamiseks sobiv vere XI hüübimisteguri kontsentraat ning meetod selle saamiseks

Info

Publication number
EE03017B1
EE03017B1 EE9400003A EE9400003A EE03017B1 EE 03017 B1 EE03017 B1 EE 03017B1 EE 9400003 A EE9400003 A EE 9400003A EE 9400003 A EE9400003 A EE 9400003A EE 03017 B1 EE03017 B1 EE 03017B1
Authority
EE
Estonia
Prior art keywords
concentrate
specific activity
high specific
therapeutic use
preparation
Prior art date
Application number
EE9400003A
Other languages
English (en)
Estonian (et)
Inventor
Burnouf Miryana
Dernis Dominique
Original Assignee
Association pour l'Essor de la Transfusion Sanguine dans la R�gion du Nord
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Association pour l'Essor de la Transfusion Sanguine dans la R�gion du Nord filed Critical Association pour l'Essor de la Transfusion Sanguine dans la R�gion du Nord
Publication of EE03017B1 publication Critical patent/EE03017B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6443—Coagulation factor XIa (3.4.21.27)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21027—Coagulation factor XIa (3.4.21.27)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EE9400003A 1991-05-07 1994-05-23 Kõrge eriaktiivsusega ja teraapiliseks kasutamiseks sobiv vere XI hüübimisteguri kontsentraat ning meetod selle saamiseks EE03017B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9105572A FR2676231A1 (fr) 1991-05-07 1991-05-07 Concentre de facteur xi de la coagulation sanguine a haute activite specifique, approprie a usage therapeutique et son procede de preparation.

Publications (1)

Publication Number Publication Date
EE03017B1 true EE03017B1 (et) 1997-08-15

Family

ID=9412593

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400003A EE03017B1 (et) 1991-05-07 1994-05-23 Kõrge eriaktiivsusega ja teraapiliseks kasutamiseks sobiv vere XI hüübimisteguri kontsentraat ning meetod selle saamiseks

Country Status (16)

Country Link
US (1) US5252217A (de)
EP (1) EP0512883B1 (de)
AT (1) ATE156360T1 (de)
AU (1) AU652043B2 (de)
BR (1) BR9201718A (de)
CA (1) CA2068069C (de)
DE (1) DE69221369T2 (de)
DK (1) DK0512883T3 (de)
EE (1) EE03017B1 (de)
ES (1) ES2107511T3 (de)
FR (1) FR2676231A1 (de)
GR (1) GR3025134T3 (de)
IL (1) IL99567A (de)
LT (1) LT3417B (de)
RU (1) RU2097047C1 (de)
UA (1) UA27733C2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL369077A1 (en) * 2001-07-20 2005-04-18 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
BRPI0416461A (pt) * 2003-11-20 2007-03-06 Novo Nordisk Healthcare Ag método para o tratamento de episódios de sangramento, formulação farmacêutica, e, uso de um polipeptìdeo fxi
US20050181978A1 (en) * 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
WO2006128497A1 (en) * 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
TW200821026A (en) * 2006-09-08 2008-05-16 Wyeth Corp Arginine wash in protein purification using affinity chromatography
EP2102335B1 (de) * 2007-01-04 2012-02-22 Crucell Holland B.V. Faktor-xi-reinigung
SI2379084T1 (en) 2008-10-15 2018-04-30 Ionis Pharmaceuticals, Inc. Modulation of factor expression 11
FR2974301B1 (fr) * 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2974366B1 (fr) * 2011-04-20 2016-06-24 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur xi
IL212911A0 (en) 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
DE102012022233A1 (de) 2012-11-14 2014-05-15 Instraction Gmbh Verfahren zur Reinigung eines (Blut)plasmaproteins
DE102012022234A1 (de) 2012-11-14 2014-05-15 Instraction Gmbh Einstufiges Verfahren zur Reinigung von (Blut)Plasmaproteinen wie Albumin aus Gemischen
FR3032621A1 (fr) 2015-02-13 2016-08-19 Lab Francais Du Fractionnement Colle biologique et son utilisation comme medicament
KR101941974B1 (ko) * 2016-11-18 2019-01-24 주식회사 녹십자 혈장 단백질 정제시 fxi의 제거방법
EP3799604A4 (de) 2018-05-09 2022-09-07 Ionis Pharmaceuticals, Inc. Verbindungen und verfahren zur verminderung der fxi-expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859340A (en) * 1976-03-15 1989-08-22 Cuno, Incorporated Filter sheet
US4783262A (en) * 1987-03-30 1988-11-08 Cuno Incorporated Separator for cell type filter element

Also Published As

Publication number Publication date
DE69221369T2 (de) 1998-03-19
IL99567A0 (en) 1992-08-18
DK0512883T3 (da) 1998-03-16
ES2107511T3 (es) 1997-12-01
CA2068069C (en) 2005-03-15
US5252217A (en) 1993-10-12
GR3025134T3 (en) 1998-02-27
ATE156360T1 (de) 1997-08-15
IL99567A (en) 1996-01-19
FR2676231B1 (de) 1995-04-21
EP0512883A1 (de) 1992-11-11
LTIP265A (en) 1994-10-25
AU1526392A (en) 1992-11-12
AU652043B2 (en) 1994-08-11
CA2068069A1 (en) 1992-11-08
DE69221369D1 (de) 1997-09-11
EP0512883B1 (de) 1997-08-06
FR2676231A1 (fr) 1992-11-13
LT3417B (en) 1995-09-25
RU2097047C1 (ru) 1997-11-27
BR9201718A (pt) 1992-12-29
UA27733C2 (uk) 2000-10-16

Similar Documents

Publication Publication Date Title
EE03017B1 (et) Kõrge eriaktiivsusega ja teraapiliseks kasutamiseks sobiv vere XI hüübimisteguri kontsentraat ning meetod selle saamiseks
IE880380L (en) Deoxyribonucleic acid for the preparation of tissue factor¹protein
NO880022L (no) Fremstilling av m-csf.
ZA863133B (en) Therapeutical application of phosphonylmethoxyalkyl adenines
IT1219874B (it) Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
ATE97813T1 (de) Mittel zur kontrolle von thrombenbildungen.
FI875319A (fi) Bisyklisten aminokarboksyylihappojen johdannaiset, menetelmä niiden valmistamiseksi ja niiden valmistuksessa käytettävät välituotteet, sekä niiden käyttö
AU7426487A (en) Method of treating depression using d-fenfluramine
AU6110490A (en) 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular diseases
HUT40695A (en) Dna sequences, recombinant dna molecules and processes for preparing humane lipocortine like polypeptides
SE8102161L (sv) "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
EP0212310A3 (en) Use of probucol in the preparation of a medicament for the treatment of heart arrhythmia
ATE40795T1 (de) Verwendung eines zerebral und peripher wirkenden antihypoxidotikums.
IT1246050B (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
RO82337A2 (ro) Bomboane medicinale pentru tratamentul afectiunilor buco-faringiene la copii
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DK0385422T3 (da) 1,4-Dihydro-5-isopropoxy-2-methyl-4-(2-trifluormethylphenyl)-1,6-naphthyridin-3-carboxylsyre-(-(N-methyl-N-phenylmethylamino)ethyl)ester-fumarat
IT8748129A0 (it) Procedimento per la tintura in sezione delle pelli
RU94031049A (ru) Способ лечения дисфункциональных расстройств организма человека
DE58901297D1 (de) Noremopamil, seine herstellung und verwendung.
BR8702799A (pt) Aparelho e metodo biomedicos para controlar a administracao de terapia a um paciente em resposta a mudancas na demanda fisiologica

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

MM4A Lapsed by not paying the annual fees

Effective date: 20100523